Annals of Surgical Oncology

, Volume 17, Issue 3, pp 846–852 | Cite as

The Adrenal Mass: Correlation of Histopathology with Imaging

  • Linwah Yip
  • Mitchell E. Tublin
  • John A. Falcone
  • Cory R. Nordman
  • Michael T. Stang
  • Jennifer B. Ogilvie
  • Sally E. Carty
  • John H. Yim
Endocrine Tumors

Abstract

Background

Computed tomography (CT) and magnetic resonance (MR) imaging can help diagnose benign adrenal adenomas, but prior studies rely on nonoperative follow-up as proof of a lesion’s benign nature. We examined adrenalectomy tissues to determine if imaging characteristics correlate with histopathologic findings.

Methods

We retrieved data for 196 consecutive adrenalectomies in 192 patients from 2000 to 2008. Imaging results were considered to signify benign adrenal adenoma if one or more of the following was present: Hounsfield units <10 on unenhanced CT, contrast-enhanced CT quantifying absolute contrast washout of >60% or relative contrast washout of >40%, or MR with chemical-shift imaging demonstrating loss of signal intensity on out-of-phase images.

Results

The sensitivity and specificity of preoperative imaging in predicting benign adrenal adenoma were 57 and 94%, respectively. Histopathology confirmed that all 66 adrenal masses with imaging characteristics suggesting benign adenoma were indeed benign lesions and included 61 benign adrenal adenomas and 5 benign nonadenomatous lesions (3 myelolipomas, 1 composite myelolipoma/adenoma, and 1 ganglioliponeuroma). The specificity of imaging in predicting benignity was 100%. Malignant adrenal lesions were diagnosed in 17/130 (13%) masses: 8 metastases, 7 adrenal cortical carcinomas, 1 epithelioid angiosarcoma, and 1 ganglioneuroblastoma. The sensitivity of imaging in identifying malignancy was 100%. No malignancies were diagnosed during postoperative follow-up (mean 6 months, range 0.2–67 months).

Conclusion

CT or MR characteristics predicted the presence of benign lesions with 100% specificity. Every adrenal malignancy had CT or MR results that were inconsistent with benign adenoma (100% sensitivity). To exclude malignancy, adrenal masses with non-benign imaging characteristics should be resected.

References

  1. 1.
    Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29:298–302.PubMedGoogle Scholar
  2. 2.
    Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190:1163–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Bülow B, Ahrén B. Swedish Research Council Study Group of Endocrine Abdominal Tumours. Adrenal incidentaloma-experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med. 2002;252:239–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000;29:159–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Sahdev A, Reznek RH. Imaging evaluation of the non-functional indeterminate adrenal mass. Trends Endocrinol Metab. 2004;15:271–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Terzolo M, Ali A, Osella G, Mazza E for the Gruppo Piemontese Incidentalomi Surrenalici. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. Arch Surg. 1997;132:914–9.PubMedGoogle Scholar
  7. 7.
    Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg. 2006;202:423–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Korobkin M, Giordao TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology. 1996;200:743–7.PubMedGoogle Scholar
  9. 9.
    Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States. Cancer. 2008;113:3130–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med. 2003;138:424–429.PubMedGoogle Scholar
  12. 12.
    Pena CS, Boland GWL, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology. 2000;217:798–902.PubMedGoogle Scholar
  13. 13.
    Boland GWL, Lee MJ, Gazelle GS, McNicholas MMJ, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. Am J Roentgenol. 1998;17:201–4.Google Scholar
  14. 14.
    Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. Am J Roentgenol. 2000;175:1411–5.Google Scholar
  15. 15.
    Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. Am J Roentgenol. 1998;170:747–52.Google Scholar
  16. 16.
    Maurea S, Imbriaco M, D’Angelillo M, Mollica C, Camera L, Salvatore M. Diagnostic accuracy of chemical-shift MR imaging to differentiate between adrenal adenomas and non adenoma adrenal lesions. Radiol Med. 2006;111:674–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Mitchell DG, Crovello M, Matteucci T, Petersen RO, Miettinen MM. Benign adrenocortical masses: diagnosis with chemical shift MR imaging. Radiology. 1992;185:345–51.PubMedGoogle Scholar
  18. 18.
    Inan N, Arslan A, Akansel G, Anik Y, Balci NC, Demirci A. Dynamic contrast enhanced MRI in the differential diagnosis of adrenal adenomas and malignant adrenal masses. Eur J Radiol. 2008;65:154–162.CrossRefPubMedGoogle Scholar
  19. 19.
    Miyake H, Maeda H, Tashiro M, et al. CT of adrenal tumors: frequency and clinical significance of low-attenuation lesions. Am J Roentgenol. 1989;152:1005–7.Google Scholar
  20. 20.
    Nwariaku FE, Champine J, Kim LT, Burkey S, O’Keefe G, Snyder WH. Radiologic characterization of adrenal masses: the role of computed tomography-derived attenuation values. Surgery. 2001;130:1068–71.CrossRefPubMedGoogle Scholar
  21. 21.
    Hamrahian AH, Ioachimescu AG, Remer EM, et al. Clinical utility of noncontrast computed tomography attenuation value (Hounsfield Units) to differentiate adrenal adenomas/hyperplasias from nonadenoomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005;90:871–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Park BK, Kim B, Ko K, Jeong SY, Kwon GY. Adrenal masses falsely diagnosed as adenomas on unenhanced and delayed contrast-enhanced computed tomography: pathological correlation. Eur Radiol. 2006;16:542–7.Google Scholar
  23. 23.
    Hönigschnabl S, Gallo S, Niederle B, Prager G, Kaserer K, Lechner G, et al. How accurate is MR imaging in characterization of adrenal masses: update of a long-term study. Eur J Radiol. 2002;41:113–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Barzon L, Sonino N, Fall F, Palù G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149:273–85.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Linwah Yip
    • 1
  • Mitchell E. Tublin
    • 2
  • John A. Falcone
    • 1
  • Cory R. Nordman
    • 2
  • Michael T. Stang
    • 1
  • Jennifer B. Ogilvie
    • 1
  • Sally E. Carty
    • 1
  • John H. Yim
    • 3
  1. 1.Department of SurgeryUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of RadiologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  3. 3.Department of SurgeryCity of Hope Cancer CenterDuarteUSA

Personalised recommendations